Conclusions:
INTRODUCTION
QbD (Quality by Design) is the modern approach for building quality in the drug product and not just tested into the product. According to ICH Q8(R1) guideline, "QbD is a systemic risk based proactive approach to pharmaceutical development that begins with predefined objectives and emphasizes product & process understanding and process control based on sound science and quality risk 1 management". QbD is concerned with predicting the quality through linking the critical material attributes (CMA) and critical process parameters (CPP) of the 2 drug product. QbD uses multivariate experiments to understand product and process and establishes a 3 design space using design of experiments (DOE). DOE is an organised method to determine the relationship between the inputs and outputs of a process. In pharmaceutical development, CMA & CPP include the factors or input variables, while CQAs (Critical Quality Attributes) include solubility and dissolution. As each unit operation involved in manufacturing has many input variables and CQAs, it is experimentally impossible to investigate all of them due to lack of time and high risk. The researchers must use the prior knowledge and experience along with the risk management to identify critical input and output variables, however the process 3 parameters are investigated by using DOE. All likely combinations of raw material attributes and process DOE is an efficient and a structured procedure for planning experiments so that the data obtained can 6 be analysed to yield valid and objective conclusions.
Screening designs are effective way to identify the significant effects. The ter m screening design refers to experimental plan that is intended to find a few significant factors from a list of many potential ones.This type of design not only provides limited amount of information about the individual variables in a given system but also requires fewest number of runs for a given 6 variable.
Response Surface Design (RSD) :
Once a screening experiment has been performed and the significant factors are determined, the next step is often to perform RSD in order to produce a prediction model, to determine curvature, detect interactions among the factors and to optimize the process. The model that is frequently used to estimate the response surface 8 is the quadratic model given with a eq.
Where, ß = the overall mean response°ß =the main effect for each factor (i=1, 2, 3….p) This design requires many runs in order to resolve this use only a fraction of the runs specified by the factorial design. In general a fraction such as ½, ? etc..,of the runs are called for by the full factorial. This design can be used when experiments are costly and when the full 8 factorial has number of design points.
PlackettBurmann design is a two level fraction factorial design commonly used for screening. In these designs the number of runs are in multiples of 4. The disadvantage of this design is that it does not consider the interactions that occur between independent variables, hence its use in optimization 9 is limited. This design is an independent quadratic equation design which does not have a fractional factorial design. It requires only three levels for each of the three factors(+1, 0 and -1). It employs 15 experimental runs with 3 factors at 3 levels and is economical than central composite design(CCD) due to less no. of trials.
These designare used when the quality characteristics of the finished product depend on proportions of substances and not on their quantities in the product 7. Central Composite Design : This designis most commonly used for non-linear responses which require second order model. It is quite popular design in response surface optimization during 10 product development in pharmaceutics.
STEPS INVOLVED IN QbD AND DOE

Quality Target Product Profile (QTTP) :
Critical Quality Attributes (CQA) :
Quality Risk Management (QRM) :
Prior to the development of DOE, QTPP and CQA must be identified by risk assessment. Basic steps in QbD is as in Fig. 2 .
According to FDA QTPP is defined as those quality attributes which are related to safety and efficacy of the drug product. Eg.sterility, purity, stability etc., it is important as it defines the product performance. Eg.Dissolution, Solubility etc.
After QTPP is assigned, the next step is to identify CQAwhich may be physical, chemical, biological or microbiological characteristic which should be present within certain limit to ensure that the desired response or product quality is met. Eg.particle size, drug-excipient ratio etc.
According to FDA, QRM is defined as a systemic process to assess and control the risk to quality of the drug product throughout its life cycle.7( Fig.1 within the acceptable ranges.
After analysing the results, a best fit combination of factors is selected and optimized. The combination is validated 10 through scaling up of the formulation.
According to ICH Q10, a control strategy is a planned set of control derived from current product and process understanding that assures process performance and product quality. It ensures that the process is maintained within the limits derives from the design space.
Ø Control of input variables based on the impact they have on process and product quality. After following these above four steps control strategy is planned:
A control strategy includes the following: Ø Control of procedure followed and facilities available. Ø Control of operations which can be possibly impact the processing of the product or its 7 quality.
After the method is optimized and validated, it can be validated for routine processing and the method processing can be monitored. It is done by using tracking system suitability data, method related investigation and so forth.
Life-cycle management is a controlled strategy used for implementation of design space in commercial stage. It includes the use of risk assessment tools at the right time and stage, which helps to prevent method failure and better understanding on the 11 design space and control strategy.
As dissolution is the most important quality control attribute for any pharmaceutical product, QbD is helpful in optimizing the drug composition in order to achieve the specified dissolution profile.
QbD is used in optimizing the generics to obtain desired pharmacokinetic profile that matches with the reference listed drug's (RLD)pharmacokinetic parameters like C T , AUC etc. which are max, max considered as CQAs.
It gives a better knowledge of the product stability and shelf life. Specifications relating to concentration of degradants and efficacy of finished product can 12 be prepared.
It can be used for developing a quality product and manufacturing process with consistent performance.
It helps in science based assessment in the "Office ofNew Drug Quality Assessment"(ONDQA). To evaluate the quality of product, to determine the Analytical methods used for the analysis of active pharmaceutical ingredient (API) and drug products for an integral part of quality by design concept as outlined in ICHQ8 guidelines. In order to develop robust, stability indicating analytical methods, a solid set of design requirements must be established in order to 9 meet the required specification of the method.
QbD is an innovative and robust technology which is very helpful to various industries including pharmaceuticals. It builds quality into the drug with less expenditure and with its predictory profile, formulation development has become easier and better. It helps to clear regulatory requirements with less risk and time. Finally it severs as an excellent tool in formulating and maintaining the quality in drug products and in optimization of various unit operations with its PAT tools. QbD ="QbD is a systemic risk based proactive approach to pharmaceutical development that begins with predefined objectives and emphasizes product & process understanding and process control based on sound science and quality risk management". DOE =DOE is an organised method to determine the relationship between the inputs and outputs of a process.
Process optimization =Process optimization is the discipline of adjusting a process so as to optimize some specified set of parameters without violating some constraint. QTPP = It is defined as the quality attributes which are related to safety and efficacy of drug product.
QbD in Process Optimization :
7. QbD in Analytical Method Development : CONCLUSION GLOSSARY CQA = It is physical,chemical, biological or microbiological characteristics which should be present within certain limit to ensure that the desired response or product quality is met.
